Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study

References

• Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319–329.
   PubMedGoogle Scholar
• Christakos S, Dhawan P, Liu Y, et al. New insights into the mechanisms of vitamin D action. J Cell Biochem. 2003;88(4):695–705.
   PubMed Web of Science ®Google Scholar
• Jones J. Metabolism and biomarkers of vitamin D. Scand J Clin Lab Invest Suppl. 2012;243:7–13.
   PubMedGoogle Scholar
• Prietl B, Treiber G, Pieber TR, et al. Vitamin D and immune function. Nutrients. 2013;5(7):2502–2521.
   PubMed Web of Science ®Google Scholar
• Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96(1):365–408.
   PubMed Web of Science ®Google Scholar
• Kulling PM, Olson KC, Olson TL, et al. Vitamin D in hematological disorders and malignancies. Eur J Haematol. 2017;98(3):187–197.
   PubMed Web of Science ®Google Scholar
• Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13(3):325–349.
   PubMed Web of Science ®Google Scholar
• Trump DL, Deeb K, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16(1):1–9.
   PubMed Web of Science ®Google Scholar
• Eissa DG, Moussa MM, Elkerdany TA. Serum 25-hydroxyvitamin D levels in relation to disease status and prognosis in acute myeloid leukemia. Egypt J Haematol. 2014;39(2):47.
   Google Scholar
• Gorle RM, Kumar MA, Ayyagari S. Effect of serum vitamin D deficiency in the prevalence of haematological malignancies. Int J Clin Biochem Res. 2018;5:185–190.
   Google Scholar
• Naz A, Qureshi RN, Shamsi TS, et al. Vitamin D levels in patients of acute leukemia before and after remission-induction therapy. Pak J Med Sci. 2013;29(1):10–14.
   PubMed Web of Science ®Google Scholar
• Seyedalipour F, Mansouri A, Vaezi M, et al. High prevalence of vitamin D deficiency in newly diagnosed acute myeloid leukemia patients and its adverse outcome. Int J Hematol Oncol Stem Cell Res. 2017;11(3):209.
   PubMedGoogle Scholar
• Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700.
   PubMed Web of Science ®Google Scholar
• Hsu JY, Feldman D, McNeal JE, et al. Reduced 1α-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001;61(7):2852–2856.
   PubMed Web of Science ®Google Scholar
• Lopes N, Sousa B, Martins D, et al. Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions vitamin D pathways unbalanced in breast lesions. BMC Cancer. 2010;10(1):1–10.
   PubMedGoogle Scholar
• Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 2000;25(2):144–146.
   PubMed Web of Science ®Google Scholar
• Höbaus J, Hummel DM, Thiem U, et al. Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J Cancer. 2013;133(6):1380–1388.
   PubMed Web of Science ®Google Scholar
• Borkowski R, Du L, Zhao Z, et al. Genetic mutation of p53 and suppression of the miR-17 ∼ 92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D signaling. Cancer Res. 2015;75(4):666–675.
   PubMed Web of Science ®Google Scholar
• Mimori K, Tanaka Y, Yoshinaga K, et al. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol. 2004;15(2):236–241.
   PubMed Web of Science ®Google Scholar
• Thomas X, Chelghoum Y, Fanari N, et al. Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies. Hematology. 2011;16(5):278–283.
   PubMed Web of Science ®Google Scholar
• Wang W, Li G, He X, et al. Serum 25-hydroxyvitamin D levels and prognosis in hematological malignancies: a systematic review and meta-analysis. Cell Physiol Biochem. 2015;35(5):1999–2005.
   PubMedGoogle Scholar
• Lee HJ, Muindi JR, Tan W, et al. Low 25 (OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer. 2014;120(4):521–529.
   PubMed Web of Science ®Google Scholar
• Radujkovic A, Schnitzler P, Ho AD, et al. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia. Clin Nutr. 2017;36(2):542–551.
   PubMed Web of Science ®Google Scholar
• Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(27):4191–4198.
   PubMed Web of Science ®Google Scholar
• Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol. 2014;32(29):3242–3248.
   PubMed Web of Science ®Google Scholar
• Consolini R, Pala S, Legitimo A, et al. Effects of vitamin D on the growth of normal and malignant B-cell progenitors. Clin Exp Immunol. 2001;126(2):214–219.
   PubMed Web of Science ®Google Scholar
• Yu W, Ge M, Lu S, et al. Decreased expression of vitamin D receptor may contribute to the hyperimmune status of patients with acquired aplastic anemia. Eur J Haematol. 2016;96(5):507–516.
   PubMed Web of Science ®Google Scholar
• Yu W, Ge M, Shi J, et al. Role of vitamin D receptor gene polymorphisms in aplastic anemia: a case-control study from China. Int J Lab Hematol. 2016;38(3):273–283.
   PubMed Web of Science ®Google Scholar
• Segersten U. 25-Hydroxyvitamin D3-1α-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metabol. 2002;87(6):2967–2972.
   PubMed Web of Science ®Google Scholar
• Tabrizi R, Moosazadeh M, Akbari M, et al. High prevalence of vitamin D deficiency among Iranian population: a systematic review and meta-analysis. Iran J Med Sci. 2018;43(2):125–139.
   PubMed Web of Science ®Google Scholar
• Vatandost S, Jahani M, Afshari A, et al. Prevalence of vitamin D deficiency in Iran: a systematic review and meta-analysis. Nutr Health. 2018;24(4):269–278.
   PubMedGoogle Scholar